Human Wharton's jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells

Stem Cell Research and Therapy

Volumn 4, Issue 3, 2013, Pages

  Du, Tao ^a   Zou, Xiangyu ^a   Cheng, Jun ^b   Wu, Shuai ^a,c   Zhong, Liang ^a   Ju, Guanqun ^a   Zhu, Jiang ^a   Liu, Guohua ^a   Zhu, Yingjian ^a   Xia, Shujie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Nantong Tongzhou People's Hospital   (China)

^c QINGDAO MUNICIPAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MESSENGER RNA; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; ACTIN; CADHERIN; CULTURE MEDIUM; SMOOTH MUSCLE ACTIN, RAT;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; FIBROGENESIS; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TUBULE EPITHELIUM; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ACUTE KIDNEY INJURY; ANIMAL; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; FIBROSIS; GENETICS; HUMAN; KIDNEY TUBULE; METABOLISM; PATHOLOGY; PHARMACOLOGY; SPRAGUE DAWLEY RAT; TIME; WHARTON JELLY;

RATTUS;

ACTINS; ACUTE KIDNEY INJURY; ANIMALS; CADHERINS; CULTURE MEDIA, CONDITIONED; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; HEPATOCYTE GROWTH FACTOR; HUMANS; KIDNEY TUBULES; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION; WHARTON JELLY;

EID: 84878388234     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt215     Document Type: Article

References (36)

1. Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Yang L, Humphreys BD, Bonventre JV, Contrib Nephrol 2011 174 149 155 21921619
2. Acute kidney injury increases risk of ESRD among elderly. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ, J Am Soc Nephrol 2009 20 223 228 10.1681/ASN.2007080837 19020007
3. The basics of epithelial-mesenchymal transition. Kalluri R, Weinberg RA, J Clin Invest 2009 119 1420 1428 10.1172/JCI39104 19487818
4. Resolved: EMT produces fibroblasts in the kidney. Zeisberg M, Duffield JS, J Am Soc Nephrol 2010 21 1247 1253 10.1681/ASN.2010060616 20651165
5. Mechanisms of tubulointerstitial fibrosis. Zeisberg M, Neilson EG, J Am Soc Nephrol 2010 21 1819 1834 10.1681/ASN.2010080793 20864689
6. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Yang J, Liu Y, Am J Pathol 2001 159 1465 1475 10.1016/S0002-9440(10)62533-3 11583974 (Pubitemid 32947976)
7. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. Yang J, Dai C, Liu Y, J Am Soc Nephrol 2005 16 68 78 15537870 (Pubitemid 43073158)
8. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Liu Y, Am J Physiol Renal Physiol 2004 287 7 F16 10.1152/ajprenal.00451.2003 15180923 (Pubitemid 38780577)
9. Mesenchymal stem cells: a new therapeutic tool for AKI. Togel FE, Westenfelder C, Nat Rev Nephrol 2010 6 179 183 10.1038/nrneph.2009.229 20186233
10. Paracrine/endocrine mechanism of stem cells on kidney repair: role of microvesicle-mediated transfer of genetic information. Camussi G, Deregibus MC, Tetta C, Curr Opin Nephrol Hypertens 2010 19 7 12 10.1097/MNH.0b013e328332fb6f 19823086
11. Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies? Ratajczak MZ, Kucia M, Jadczyk T, Greco NJ, Wojakowski W, Tendera M, et al. Leukemia 2012 26 1166 1173 10.1038/leu.2011.389 22182853
12. Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies? Ratajczak MZ, Kucia M, Jadczyk T, Greco NJ, Wojakowski W, Tendera M, et al. Leukemia 2012 26 1166 1173 10.1038/leu.2011.389 22182853
13. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Nakamura T, Mizuno S, Proc Jpn Acad Ser B Phys Biol Sci 2010 86 588 610 10.2183/pjab.86.588 20551596
14. The alleviation of acute and chronic kidney injury by human Wharton's jelly-derived mesenchymal stromal cells triggered by ischemia-reperfusion injury via an endocrine mechanism. Du T, Cheng J, Zhong L, Zhao XF, Zhu J, Zhu YJ, et al. Cytotherapy 2012 14 1215 1227 10.3109/14653249.2012.711471 22920838
15. Minimal criteria for defining multipotent mesenchymal stromal cells: the International Society for Cellular Therapy position statement. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Cytotherapy 2006 8 315 317 10.1080/14653240600855905 16923606 (Pubitemid 44269669)
16. Stromal cells protect against acute tubular injury via an endocrine effect. Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG, J Am Soc Nephrol 2007 18 2486 2496 10.1681/ASN.2007020140 17656474 (Pubitemid 47378865)
17. EMT and proteinuria as progression factors. Strutz FM, Kidney Int 2009 75 475 481 10.1038/ki.2008.425 18716603
18. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Boor P, Ostendorf T, Floege J, Nat Rev Nephrol 2010 6 643 656 20838416
19. The origin of interstitial myofibroblasts in chronic kidney disease. Grgic I, Duffield JS, Humphreys BD, Pediatr Nephrol 2012 27 183 193 10.1007/s00467-011-1772-6 21311912
20. Bone marrow mononuclear cells attenuate fibrosis development after severe acute kidney injury. Semedo P, Donizetti-Oliveira C, Burgos-Silva M, Cenedeze MA, Avancini Costa Malheiros DM, Pacheco-Silva A, et al. Lab Invest 2010 90 685 695 10.1038/labinvest.2010.45 20308984
21. Arterially delivered mesenchymal stem cells prevent obstruction-induced renal fibrosis. Asanuma H, Vanderbrink BA, Campbell MT, Hile KL, Zhang H, Meldrum DR, et al. J Surg Res 2011 168 51 e59 10.1016/j.jss.2010.06.022 20850784
22. Renal recovery following acute kidney injury. Macedo E, Bouchard J, Mehta RL, Curr Opin Crit Care 2008 14 660 665 10.1097/MCC.0b013e328317ee6e 19005306
23. Renotropic functions of hepatocyte growth factor in renal regeneration after unilateral nephrectomy. Nagaike M, Hirao S, Tajima H, Noji S, Taniguchi S, Matsumoto K, et al. J Biol Chem 1991 266 22781 22784 1660459 (Pubitemid 21908716)
24. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV, Nat Med 2010 16 535 543 1p following 143 10.1038/nm.2144 20436483
25. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, et al. Am J Pathol 2010 176 85 97 10.2353/ajpath.2010. 090517 20008127
26. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Burns WC, Kantharidis P, Thomas MC, Cells Tissues Organs 2007 185 222 231 10.1159/000101323 17587828 (Pubitemid 46956862)
27. New insights into epithelial-mesenchymal transition in kidney fibrosis. Liu Y, J Am Soc Nephrol 2010 21 212 222 10.1681/ASN.2008121226 20019167
28. TGF-beta and epithelial-to-mesenchymal transitions. Zavadil J, Bottinger EP, Oncogene 2005 24 5764 5774 10.1038/sj.onc.1208927 16123809 (Pubitemid 43086136)
29. Blockage of tubular epithelial to myofibroblast transition by hepatocyte growth factor prevents renal interstitial fibrosis. Yang J, Liu Y, J Am Soc Nephrol 2002 13 96 107 11752026 (Pubitemid 34042016)
30. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Liu Y, Rajur K, Tolbert E, Dworkin LD, Kidney Int 2000 58 2028 2043 10.1111/j.1523-1755.2000.00375.x 11044223
31. Hepatocyte growth factor gene therapy retards the progression of chronic obstructive nephropathy. Gao X, Mae H, Ayabe N, Takai T, Oshima K, Hattori M, et al. Kidney Int 2002 62 1238 1248 10.1111/j.1523-1755.2002.kid579.x 12234294
32. Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy. Mizuno S, Matsumoto K, Nakamura T, Kidney Int 2001 59 1304 1314 10.1046/j.1523-1755.2001.0590041304.x 11260391 (Pubitemid 32281218)
33. Actions of hepatocyte growth factor as a local modulator in the kidney: potential role in pathogenesis of renal disease. Yo Y, Morishita R, Yamamoto K, Tomita N, Kida I, Hayashi S, et al. Kidney Int 1998 53 50 58 10.1046/j.1523-1755.1998.00726.x 9452999 (Pubitemid 28066902)
34. The antifibrogenic effect of hepatocyte growth factor (HGF) on renal tubular (HK-2) cells is dependent on cell growth. Esposito C, Parrilla B, Cornacchia F, Grosjean F, Mangione F, Serpieri N, et al. Growth Factors 2009 27 173 180 10.1080/08977190902834077 19301208
35. Life-sparing effect of human cord blood-mesenchymal stem cells in experimental acute kidney injury. Morigi M, Rota C, Montemurro T, Montelatici E, Lo Cicero V, Imberti B, et al. Stem Cells 2010 28 513 522 20049901
36. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al. J Am Soc Nephrol 2009 20 1053 1067 10.1681/ASN.2008070798 19389847